发明申请
US20100260765A1 TARGETED BINDING AGENTS DIRECTED TO KDR AND USES THEREOF - 035
有权
针对KDR的针对性的绑定代理及其使用 - 035
- 专利标题： TARGETED BINDING AGENTS DIRECTED TO KDR AND USES THEREOF - 035
- 专利标题（中）： 针对KDR的针对性的绑定代理及其使用 - 035
-
申请号： US12669724申请日： 2008-07-23
-
公开(公告)号： US20100260765A1公开(公告)日： 2010-10-14
- 发明人: Simon Thomas Barry , Vahe Bedian , Bradley Hedberg , Jaspal Singh Kang , Qing Zhou
- 申请人： Simon Thomas Barry , Vahe Bedian , Bradley Hedberg , Jaspal Singh Kang , Qing Zhou
- 申请人地址： SE Sodertalje GB London
- 专利权人： AstraZeneca AB,AstraZeneca UK Limited
- 当前专利权人： AstraZeneca AB,AstraZeneca UK Limited
- 当前专利权人地址： SE Sodertalje GB London
- 国际申请： PCT/GB08/50615 WO 20080723
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; C07K16/18 ; C07H21/04 ; C12N15/63 ; C12N5/00 ; A61P35/04
摘要：
The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.